×

收藏-健康网会员访问记录

网页标题:
×

注册健康网用户

用 户 名:
联 系 人:
性  别:
密  码:
重复密码:
电子邮箱:
邮箱验证码:
固定电话:
传  真:
手  机:
单位名称:
通信地址:
首选栏目:
×

找回密码

  • 1.选择找回方式
  • 2.确认验证信息
  • 3.修改密码
  • 4.修改成功
  • 找回方式:
  • 用 户 名:
  • 手机号码:

 您现在位置:健康网-医药产业 >> 研究报告 >> English reports >> English reports >> 浏览医药行业研究报告

Cardiovascular drugs report

作者:wangchun   来源:本站原创    点击数:0    更新时间:2006-11-14 11:27:11

[关键字]: Calcium antagonist Antiarrhythic anti-anginal

健康网讯:

Research Report on Chinese cardiovascular drugs Market
Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published: 
Format:  Hardcopy and Adobe PDF 
Price:  US$2,500 
Contact: Mr. Bian chenghua   Ms. Wu huifang
Tel.: 86-10-68012929-2116/2101             Fax:  86-10-68012929-2008
E-mail: bianch@healthoo.com   wuhf@healthoo.com 


1. Classification of cardiovascular diseases and disease incidence
  1.1 Overview of cardiovascular diseases
    1.1.1 Categories of cardiovascular diseases
    1.1.2 World epidemiology trend of cardiovascular diseases
  1.2 Disease incidence and mortality of cardiovascular diseases in
 China
    1.2.1 Epidemiology trend and the characteristic in the 90's of las
t
 century
    1.2.2 Epidemiology of key cardiovascular diseases and disease
 incidence
    1.2.3 Rank of cardiovascular diseases by mortality in the past
 few years
2 Categories of cardiovascular drugs
  2.1 Categories classified according to action function and indication
  2.2 Categories classified according to pharmacologic action and
 clinic usage
    2.2.1 Calcium antagonist
    2.2.2 For cardiac insufficiency
    2.2.3 Antiarrhythic drug
    2.2.4 anti-anginal drug
    2.2.5 Vasodilator
    2.2.6 Antihypertensive
    2.2.7 Antishock drug
    2.2.8 Antiatherosclerotic
  2.3 Amount of breeds of cardiovascular drugs
3 Production status of bulk durgs of cardiovascular drugs
  3.1 Proportion of bulk durgs of cardiovascular drugs in the output of
 all  bulk drugs
  3.2 Output descended compared to 1999 year
  3.3 Domestic manufacturers of bulk durgs of cardiovascular drugs
  3.4 Production status of all  bulk drugs
  3.5 Export & import amount of bulk durgs of cardiovascular drugs
 was small
4 Market analysis of cardiovascular drugs
  4.1 Summary
  4.2 Sales status of the global market
  4.3 Market analysis of Chinese market about the past 3 years
    4.3.1 Market share of cardiovascular drugs in the whole drug market
    4.3.2 Market share of Antihypertensives
    4.3.3 Market share of Antiarrhythic drugs
    4.3.4 Market share of anti-anginal drugs
    4.3.5 Market share of drugs for heart failure
    4.3.6 Market share of Antishock drugs
    4.3.7 Market share of vasodilators
    4.3.8 Market share of lipid regulators
  4.4 Sales analysis of key breeds
    4.4.1 amlodipine
    4.4.2 Isosorbide Mononitrate
    4.4.3 Captopril
    4.4.4 Nifedipine
    4.4.5 Benazepril
    4.4.6 Simvastatin
    4.4.7 ginkgo leaf
    4.4.8 Danshen Root
    4.4.9 Daidzein
  4.5 Introductions of key manufacturers
    4.5.1 Shenzhen neptunus Pharmaceutical Co.Ltd
    4.5.2 Tasly Group
    4.5.3 Chendu Di'ao Group
    4.5.4 Jiangsu Yangtze river Pharmaceutical Group Company Ltd
5 Research and development of cardiovascular drugs
  5.1 Overview
  5.2 Research focus of Calcium antagonists
    5.2.1 Research focus of long-acting and lipophilia dihydropyridines
 calcium antagonists
    5.2.2 Research focus of T-type Calcium Channel antagonists
    5.2.3 Calcium antagonist of traditional Chinese medicine
    5.2.4 Tetrandrine
  5.3 Research focus of Angiotensin converting enzyme inhibitors(ACEI)
    5.3.1 The first generation such as "capt"
    5.3.2 Second generation (prodrug without hydrosulfuryl such as
 Enalapril)
    5.3.3 Third generation (such as Lisinopril, Fosinopril)
  5.4 Research focus of antihypertensive drugs 
    5.4.1 NEP-ACE inhibitor
    5.4.2 ACEI inhibitor
    5.4.3 AT1 receptor antagonist
  5.5 Research progress of sustained-release preparation of
 cardiovascular drugs
    5.5.1 Captopril sustained-release matrix tablets
    5.5.2 Felodipine sustained-release tablets
    5.5.3 Nitroglycerin sustained-release tablets
    5.5.4 Isradipine sustained-release capsules
    5.5.5 Verapamil sustained-release tablets
    5.5.6 Isosorbide Mononitrate sustained-release tablets
    5.5.7 Nifedipine sustained-release tablets
    5.5.8 Atenolol sustained-release tablets
    5.5.9 Aspirin sustained-release capsules
    5.5.10 Nicardipine sustained-release pellets
    5.5.11 Diltiazem sustained-release tablets
    5.5.12 Nitrendipine sustained-release pellets
  5.6 Research progress of new technologies of cardiovascular drugs
    5.6.1 Oral pulse release system
    5.6.2 Transdermal therapeutic system(TTS)
    5.6.3 Colon specific drug delivery system
    5.6.4 Solid dispersion system
  5.7 Others
    5.7.1 GPⅡb/Ⅲa
    5.7.2 Reserah progress for heart failure
    5.7.3 Reserah progress of plant medicine for cardiovascular
 diseases
    5.7.4 Drugs of restenosis preventio
    5.7.5 New statin Rosuvastatin Calcium
  5.8 Research and development of cardiovascular drugs of key
 enterprises
    5.8.1 AstraZeneca
    5.8.2 Bristol Myers Squibb
    5.8.3 Merck
    5.8.4 Pfizer Inc 
    5.8.5 Sanofi-Synthelabo
6 SWOT analysis of the industry of cardiovascular drugs in China
  6.1 Strength 
     6.1.1 Pharmacodynamic action of domestic drugs is equal to
 import drugs
     6.1.2 Prices of domestic drugs are more competitive
  6.2 weakness
    6.2.1 Domestic drugs compete with import drugs
    6.2.2 China lags to powerful nations of pharmaceutical industry
  6.3 opportunity
    6.3.1 The broad market prospect 
    6.3.2 Consumption level of cardiovascular drugs would increase
    6.3.3 About jiangsu Yangtze river pharmaceutical group company Ltd
  6.4 threat
Cardiovascular drugs report
注册后,我们会为你提供报告样本并为您提供更全面的咨询服务
您的姓名  称谓: 先生女士
手机号码 
验证号码 
电子邮件 
单位名称 

服务热线

  • 联系项目:86-10-68012929-2103
  • 订购报告:86-10-68012929-2121
  • 邮件订购:leigy@healthoo.com